Erbitux renews RSA for the first time

Published: 2018-05-16 16:29:00
Updated: 2018-05-16 16:04:50

Erbitux, a metastatic rectal and colon cancer therapy, successfully renewed the RSA agreement. This is the first case which renewed the agreement through a renegotiation.

According to the National Health Insurance Service(NHIS) on the 14th, Merck and the NHIS have concluded the RSA revaluation a...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.